JP2004516302A5 - - Google Patents

Download PDF

Info

Publication number
JP2004516302A5
JP2004516302A5 JP2002552504A JP2002552504A JP2004516302A5 JP 2004516302 A5 JP2004516302 A5 JP 2004516302A5 JP 2002552504 A JP2002552504 A JP 2002552504A JP 2002552504 A JP2002552504 A JP 2002552504A JP 2004516302 A5 JP2004516302 A5 JP 2004516302A5
Authority
JP
Japan
Prior art keywords
aztreonam
composition according
dry powder
composition
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002552504A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004516302A (ja
JP4646489B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/050062 external-priority patent/WO2002051356A2/en
Publication of JP2004516302A publication Critical patent/JP2004516302A/ja
Publication of JP2004516302A5 publication Critical patent/JP2004516302A5/ja
Application granted granted Critical
Publication of JP4646489B2 publication Critical patent/JP4646489B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002552504A 2000-12-27 2001-12-20 肺細菌感染症の治療及び予防のための吸入可能なアズトレオナム Expired - Lifetime JP4646489B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25842300P 2000-12-27 2000-12-27
PCT/US2001/050062 WO2002051356A2 (en) 2000-12-27 2001-12-20 Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections

Publications (3)

Publication Number Publication Date
JP2004516302A JP2004516302A (ja) 2004-06-03
JP2004516302A5 true JP2004516302A5 (enExample) 2010-05-20
JP4646489B2 JP4646489B2 (ja) 2011-03-09

Family

ID=22980480

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002552504A Expired - Lifetime JP4646489B2 (ja) 2000-12-27 2001-12-20 肺細菌感染症の治療及び予防のための吸入可能なアズトレオナム

Country Status (19)

Country Link
US (6) US6660249B2 (enExample)
EP (2) EP1353647B1 (enExample)
JP (1) JP4646489B2 (enExample)
AT (1) ATE502623T1 (enExample)
AU (1) AU2002231244B2 (enExample)
BE (1) BE2011C029I2 (enExample)
BR (1) BRPI0116757B8 (enExample)
CA (2) CA2433280C (enExample)
CY (2) CY1111571T1 (enExample)
DE (2) DE60144291D1 (enExample)
DK (2) DK1353647T3 (enExample)
ES (2) ES2406405T3 (enExample)
FR (1) FR11C0030I2 (enExample)
IL (3) IL156596A0 (enExample)
LU (1) LU91851I2 (enExample)
NL (1) NL300492I2 (enExample)
NO (3) NO329643B1 (enExample)
PT (2) PT2301524E (enExample)
WO (1) WO2002051356A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
IL156596A0 (en) * 2000-12-27 2004-01-04 Salus Pharma Inc Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
US20030133925A1 (en) * 2001-09-28 2003-07-17 Shawar Ribhi M. Monobactam compositions and methods of use thereof
CA2477982A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. Methods for entrapment of bioactive agent in a liposome or lipid complex
US7607436B2 (en) 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
AU2003265373A1 (en) 2002-08-05 2004-02-23 Teva Gyogyszergyar Reszvenytarsasag Preparation of aztreonam
AU2002356646A1 (en) * 2002-12-11 2004-06-30 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
WO2004093848A2 (en) * 2003-04-14 2004-11-04 Vectura Ltd Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
WO2004103999A1 (en) 2003-05-15 2004-12-02 TEVA Gyógyszergyár Részvénytársaság AZTREONAM β POLYMORPH WITH VERY LOW RESIDUAL SOLVENT CONTENT
CA2526362C (en) * 2003-05-20 2012-10-09 James F. Collins Ophthalmic drug delivery system
WO2005005424A1 (en) * 2003-07-02 2005-01-20 TEVA Gyógyszergyár Részvénytársaság Aztreonam l-lysine and methods for the preparation thereof
AU2004257632C1 (en) * 2003-07-03 2010-04-15 Gilead Sciences, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
AU2014271333B2 (en) * 2003-07-03 2016-10-27 Gilead Sciences, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7452523B2 (en) * 2004-01-27 2008-11-18 Gilead Sciences, Inc. Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
ATE423115T1 (de) 2005-05-09 2009-03-15 Sicor Inc Herstellungsverfahren für aztreonam
WO2008039987A2 (en) * 2006-09-28 2008-04-03 Transave, Inc. Methods of treating pulmonary distress
HUP0700007A2 (en) * 2007-01-08 2008-10-28 Asthma Rehabilitacios Ct Kft Device and process for producing of natrium chloride aerosol for the disorders of the respiratory system
EP2155251B1 (en) * 2007-05-08 2013-09-25 Rq Bioscience, Inc. Therapeutic compositions and methods for treating gram-negative bacterial infections
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
KR20100093037A (ko) * 2007-10-01 2010-08-24 길리애드 사이언시즈, 인코포레이티드 폐질환의 건강 관련 삶의 질 부족을 치료하기 위한 흡입용 아즈트레오남 라이신
HUE034051T2 (en) 2007-11-27 2018-01-29 Algipharma As Use of alginate-containing oligomers to combat biofilms
EP2098219A1 (en) 2008-03-05 2009-09-09 PARI Pharma GmbH Macrolide compositions having improved taste and stability
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
ES2625260T5 (es) 2009-03-26 2020-07-29 Pulmatrix Operating Co Inc Formulaciones de polvo seco y métodos para el tratamiento de enfermedades pulmonares
US8815831B2 (en) 2009-06-03 2014-08-26 Algipharma As Treatment of Acinetobacter with alginate oligomers and antibiotics
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
US9061352B2 (en) 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US20120076859A1 (en) * 2010-09-23 2012-03-29 Activaero Gmbh Targeted Lung Delivery of Citrulline and/or Another Nitric Oxide Precursor and a Method for Treatment of Pulmonary Deficiency of Nitric Oxide in Cystic Fibrosis and Other Pulmonary Diseases
EP3470057B1 (en) 2010-09-29 2021-11-03 Pulmatrix Operating Company, Inc. Cationic dry powders comprising magnesium salt
CA3086367A1 (en) 2010-09-29 2012-04-05 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
WO2013109217A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Pharmaceutical formulations comprising aztreonam
EP2819672A1 (en) 2012-02-29 2015-01-07 Pulmatrix, Inc. Inhalable dry powders
CA2910825A1 (en) * 2013-03-28 2014-10-02 Pharmacaribe, Llc Compositions, formulations and methods of bio-balancing the ph of sterile isotonic saline and hypertonic saline solutions
MX2015013845A (es) 2013-04-01 2016-05-09 Pulmatrix Inc Polvos secos de tiotropio.
CN104784159A (zh) * 2015-04-15 2015-07-22 苏州惠仁生物科技有限公司 氨曲南粉雾剂的制备方法
JP6774508B2 (ja) 2016-05-03 2020-10-28 ニューマ・リスパイラトリー・インコーポレイテッド 流体を肺系に供給するための液滴送達装置、及びその使用方法
WO2017192773A1 (en) 2016-05-03 2017-11-09 Pneuma Respiratory, Inc. Methods for treatment of pulmonary lung diseases with improved therapeutic efficacy and improved dose efficiency
WO2017192782A1 (en) * 2016-05-03 2017-11-09 Pneuma Respiratory, Inc. Systems and methods comprising a droplet delivery device and a breathing assist device for therapeutic treatment
EP4591994A3 (en) 2016-05-03 2025-10-01 Pneuma Respiratory, Inc. A droplet delivery device for generating and delivering droplets to the pulmonary system
US11285274B2 (en) 2016-05-03 2022-03-29 Pneuma Respiratory, Inc. Methods for the systemic delivery of therapeutic agents to the pulmonary system using a droplet delivery device
CA3064005C (en) 2017-05-19 2023-03-07 Pneuma Respiratory, Inc. Dry powder delivery device and methods of use
AU2018279940B2 (en) 2017-06-10 2023-12-14 Eyenovia, Inc. Methods and devices for handling a fluid and delivering the fluid to the eye
WO2019071008A1 (en) 2017-10-04 2019-04-11 Pneuma Respiratory, Inc. ELECTRONIC DEVICE FOR DELIVERY OF LINEAR SHAPE ADMINISTRATION OPERATED BY BREATHING AND METHODS OF USE
CA3079189A1 (en) 2017-10-17 2019-04-25 Pneuma Respiratory, Inc. Nasal drug delivery apparatus and methods of use
CA3082192A1 (en) 2017-11-08 2019-05-16 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use
CN110898040B (zh) * 2018-09-18 2022-05-17 北京盈科瑞创新药物研究有限公司 一种吸入用氨曲南溶液用冻干粉及其制备方法
US12208061B2 (en) * 2019-02-28 2025-01-28 Exorao Life Science S.R.L. Sterile aztreonam package
CA3164288A1 (en) 2019-12-11 2021-06-17 Eyenovia, Inc. Systems and devices for delivering fluids to the eye and methods of use
CN111647537B (zh) * 2020-06-18 2022-04-26 浙江工业大学 一种耐盐辣椒素降解菌、应用及餐厨垃圾处理方法
PL4359046T3 (pl) 2021-06-22 2025-10-13 Pneuma Respiratory, Inc. Urządzenie do podawania kropelkowego z wyrzutem wypychającym
KR20250038748A (ko) 2022-07-18 2025-03-19 뉴마 레스퍼러토리 인코포레이티드 작은 스텝 크기 및 고해상도 에어로졸 생성 시스템 및 방법

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126A (en) * 1852-07-13 Marcus r
US572801A (en) * 1896-12-08 Telephone-exchange
US610824A (en) * 1898-09-13 Sleigh attachment for vehicles
US673739A (en) * 1900-09-19 1901-05-07 Frank B Stearns Driving mechanism for vehicles.
US775670A (en) * 1904-08-17 1904-11-22 Thomas F Whittelsey Air-brake safety device.
US946838A (en) * 1909-08-17 1910-01-18 George Dawson Tempering compound.
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
WO1982001873A1 (en) * 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
US4673739A (en) 1980-12-05 1987-06-16 Takeda Chemical Industries, Ltd. 4-carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
US4529698A (en) * 1981-01-19 1985-07-16 E. R. Squibb & Sons, Inc. Process for preparing a 2-oxo-1-azetidinesulfonic acid salt
US4386034A (en) * 1981-02-02 1983-05-31 E. R. Squibb & Sons, Inc. Sulfamated amino acid amides
US4625022A (en) * 1981-02-02 1986-11-25 E. R. Squibb & Sons, Inc. Process for preparing (s)-3-amino-2-oxo-1-azetidinesulfonic acid salts
US4572801A (en) 1981-04-30 1986-02-25 Takeda Chemical Industries, Ltd. 4-Carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
CA1181075A (en) 1981-07-13 1985-01-15 David M. Floyd CRYSTALLINE ANHYDROUS FORM OF [3-S-[3.alpha.(Z),4 .beta.]]-3-[[(2-AMINO-4-THIAZOLYL) [(1-CARBOXY-1-METHYLETHOXY)IMINO]ACETYL] AMINO]-4-METHYL-2-OXO-1-AZETIDINESULFONIC ACID
US4946838A (en) 1981-07-13 1990-08-07 E. R. Squibb & Sons, Inc. Crystalline anhydrous aztreonam
US4752469A (en) * 1984-01-09 1988-06-21 E. R. Squibb & Sons, Inc. Potentiators of beta-lactam antibiotics
US4826973A (en) * 1984-07-20 1989-05-02 E. R. Squibb & Sons, Inc. Delta form of aztreonam and preparation thereof
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US4888998A (en) * 1986-07-11 1989-12-26 Beckman Instruments, Inc. Sample handling system
CA1339136C (en) 1987-07-01 1997-07-29 Sailesh Amilal Varia Amorphous form of aztreonam
US5194604A (en) * 1990-06-29 1993-03-16 E. R. Squibb & Sons, Inc. Process and intermediates for beta-lactams having aminothiazole(iminooxyacetic acid)acetic acid sidechains
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
CA2105629A1 (en) * 1992-09-14 1994-03-15 Robert S. Becker Potentiation of immunogenic response
EP0754050B1 (en) * 1994-01-14 2002-06-26 XOMA Technology Ltd. Anti gram positive bacterial methods and materials
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5662929A (en) * 1994-12-23 1997-09-02 Universite De Montreal Therapeutic liposomal formulation
US5723495A (en) 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
CA2639051A1 (en) 1996-09-04 1998-03-12 Takara Bio Inc. Fungal antigens and process for producing the same
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
CA2410694A1 (en) 1998-06-16 1999-12-16 Serge Dea Porcine reproductive and respiratory syndrome virus (prrsv) dna vaccines
CA2514899A1 (en) 1998-08-31 2000-03-09 Biogen, Inc. Method of modulating memory effector t-cells and compositions
SI20959A (sl) * 1998-12-17 2003-02-28 Pathogenesis Corporation Metoda za zdravljenje hudega kroničnega bronhitisa (bronhiektazije) z aerosoliziranimi antibiotiki
WO2000073337A1 (en) 1999-06-01 2000-12-07 Biogen, Inc. Polymer conjugates of hedgehog proteins and uses
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
IL149085A0 (en) * 1999-10-29 2002-11-10 Inhale Therapeutic Syst A dry powder composition containing a di or tripeptide
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
IL156596A0 (en) 2000-12-27 2004-01-04 Salus Pharma Inc Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
WO2003031163A2 (en) * 2001-10-08 2003-04-17 California Institute Of Technology Microfabricated lenses, methods of manufacture thereof, and applications therefor
MXPA04003879A (es) 2001-10-24 2005-02-17 Pari Gmbh Equipo para la preparacion de una composicion farmaceutica.
CA2477982A1 (en) 2002-03-05 2003-09-18 Transave, Inc. Methods for entrapment of bioactive agent in a liposome or lipid complex
EP1417958A1 (en) 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
AU2002356646A1 (en) 2002-12-11 2004-06-30 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
WO2005005424A1 (en) 2003-07-02 2005-01-20 TEVA Gyógyszergyár Részvénytársaság Aztreonam l-lysine and methods for the preparation thereof
KR20100093037A (ko) 2007-10-01 2010-08-24 길리애드 사이언시즈, 인코포레이티드 폐질환의 건강 관련 삶의 질 부족을 치료하기 위한 흡입용 아즈트레오남 라이신

Similar Documents

Publication Publication Date Title
JP2004516302A5 (enExample)
EP1991201B1 (en) Nebulised antibiotics for inhalation therapy
US10149823B2 (en) Dry powder formulations and methods of use
JP5863641B2 (ja) 濃縮肥満細胞安定化用薬学的調合物
JP2008536546A5 (enExample)
CA2433280A1 (en) Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
JP2004535454A (ja) エーロゾル化用に至適化されたトブラマイシン製剤
JP2012522012A (ja) 粘膜内層の生物物理学的性質の改変のためのクエン酸カルシウムおよび乳酸カルシウム製剤
CN114652704A (zh) 一种曲前列尼尔软雾吸入剂
EP3179986B1 (en) Dry powder formulations for inhalation
US20130291860A1 (en) Method For Treating Cystic Fibrosis with Inhaled Denufosol
WO2022116792A1 (zh) 一种用于治疗肺结核的异烟肼干粉吸入剂
US20140377365A1 (en) Sustained-release formulation of rotigotine
TWI762449B (zh) 噴霧器用組成物
EP4516297A1 (en) Treprostinil soft mist inhalant
WO2001015777A1 (en) Pulmonary-administration of mineral ascorbates
CN111544420B (zh) 可吸入泡腾粉雾剂及其在制备感染性肺炎药物中的应用
US20080319079A1 (en) Method for Administering Formoterol Using a Nebulizer
Lalan et al. Inhalation Drug Therapy: Emerging Trends in Nasal and Pulmonary Drug
Wang et al. Materials Today Bio
NP et al. PULMONARY DRUG DELIVERY SYSTEM
HK1240081A1 (en) Dry powder formulations for inhalation